Medical Care
Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Research Report 2025
- Jul 08, 25
- ID: 347808
- Pages: 71
- Figures: 75
- Views: 33
The global market for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment.
The Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Seattle Genetics
Merck
Bristol-Myers Squibb
Genmab AS
Takeda Pharmaceutical
Eisai Co., Ltd.
Cellerant Therapeutics
Segment by Type
Chemotherapy
Radiation Therapy
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment.
The Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Seattle Genetics
Merck
Bristol-Myers Squibb
Genmab AS
Takeda Pharmaceutical
Eisai Co., Ltd.
Cellerant Therapeutics
Segment by Type
Chemotherapy
Radiation Therapy
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Radiation Therapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Perspective (2020-2031)
2.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Growth Trends by Region
2.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Dynamics
2.3.1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Industry Trends
2.3.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Drivers
2.3.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Challenges
2.3.4 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue
3.1.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue (2020-2025)
3.1.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue
3.4 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio
3.4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2024
3.5 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Head office and Area Served
3.6 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Product and Application
3.7 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by Type
4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Type (2026-2031)
5 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by Application
5.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
6.2 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
6.4 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
7.2 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
7.4 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
9.2 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
9.4 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.1.4 Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.2.4 Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Seattle Genetics
11.3.1 Seattle Genetics Company Details
11.3.2 Seattle Genetics Business Overview
11.3.3 Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.3.4 Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.3.5 Seattle Genetics Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.4.4 Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.5.4 Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Genmab AS
11.6.1 Genmab AS Company Details
11.6.2 Genmab AS Business Overview
11.6.3 Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.6.4 Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.6.5 Genmab AS Recent Development
11.7 Takeda Pharmaceutical
11.7.1 Takeda Pharmaceutical Company Details
11.7.2 Takeda Pharmaceutical Business Overview
11.7.3 Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.7.4 Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.7.5 Takeda Pharmaceutical Recent Development
11.8 Eisai Co., Ltd.
11.8.1 Eisai Co., Ltd. Company Details
11.8.2 Eisai Co., Ltd. Business Overview
11.8.3 Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.8.4 Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.8.5 Eisai Co., Ltd. Recent Development
11.9 Cellerant Therapeutics
11.9.1 Cellerant Therapeutics Company Details
11.9.2 Cellerant Therapeutics Business Overview
11.9.3 Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.9.4 Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.9.5 Cellerant Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Radiation Therapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Perspective (2020-2031)
2.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Growth Trends by Region
2.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Dynamics
2.3.1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Industry Trends
2.3.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Drivers
2.3.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Challenges
2.3.4 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue
3.1.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue (2020-2025)
3.1.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue
3.4 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio
3.4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2024
3.5 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Head office and Area Served
3.6 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Product and Application
3.7 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by Type
4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Type (2026-2031)
5 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by Application
5.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
6.2 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
6.4 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
7.2 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
7.4 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
9.2 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
9.4 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.1.4 Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.2.4 Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Seattle Genetics
11.3.1 Seattle Genetics Company Details
11.3.2 Seattle Genetics Business Overview
11.3.3 Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.3.4 Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.3.5 Seattle Genetics Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.4.4 Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.5.4 Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Genmab AS
11.6.1 Genmab AS Company Details
11.6.2 Genmab AS Business Overview
11.6.3 Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.6.4 Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.6.5 Genmab AS Recent Development
11.7 Takeda Pharmaceutical
11.7.1 Takeda Pharmaceutical Company Details
11.7.2 Takeda Pharmaceutical Business Overview
11.7.3 Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.7.4 Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.7.5 Takeda Pharmaceutical Recent Development
11.8 Eisai Co., Ltd.
11.8.1 Eisai Co., Ltd. Company Details
11.8.2 Eisai Co., Ltd. Business Overview
11.8.3 Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.8.4 Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.8.5 Eisai Co., Ltd. Recent Development
11.9 Cellerant Therapeutics
11.9.1 Cellerant Therapeutics Company Details
11.9.2 Cellerant Therapeutics Business Overview
11.9.3 Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
11.9.4 Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
11.9.5 Cellerant Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Others
Table 5. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2020-2025)
Table 9. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2026-2031)
Table 11. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Trends
Table 12. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Drivers
Table 13. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Challenges
Table 14. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Restraints
Table 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players (2020-2025)
Table 17. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2024)
Table 18. Ranking of Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Headquarters and Area Served
Table 21. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Product and Application
Table 22. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Type (2020-2025)
Table 26. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Type (2026-2031)
Table 28. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Application (2020-2025)
Table 30. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Application (2026-2031)
Table 32. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 47. Roche Company Details
Table 48. Roche Business Overview
Table 49. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 50. Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Novartis Company Details
Table 53. Novartis Business Overview
Table 54. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 55. Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Seattle Genetics Company Details
Table 58. Seattle Genetics Business Overview
Table 59. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 60. Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 61. Seattle Genetics Recent Development
Table 62. Merck Company Details
Table 63. Merck Business Overview
Table 64. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 65. Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 66. Merck Recent Development
Table 67. Bristol-Myers Squibb Company Details
Table 68. Bristol-Myers Squibb Business Overview
Table 69. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 70. Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 71. Bristol-Myers Squibb Recent Development
Table 72. Genmab AS Company Details
Table 73. Genmab AS Business Overview
Table 74. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 75. Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 76. Genmab AS Recent Development
Table 77. Takeda Pharmaceutical Company Details
Table 78. Takeda Pharmaceutical Business Overview
Table 79. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 80. Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 81. Takeda Pharmaceutical Recent Development
Table 82. Eisai Co., Ltd. Company Details
Table 83. Eisai Co., Ltd. Business Overview
Table 84. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 85. Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 86. Eisai Co., Ltd. Recent Development
Table 87. Cellerant Therapeutics Company Details
Table 88. Cellerant Therapeutics Business Overview
Table 89. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 90. Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 91. Cellerant Therapeutics Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
Table 95. Authors List of This Report
List of Figures
Figure 1. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Picture
Figure 2. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Type: 2024 VS 2031
Figure 4. Chemotherapy Features
Figure 5. Radiation Therapy Features
Figure 6. Others Features
Figure 7. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Report Years Considered
Figure 14. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region: 2024 VS 2031
Figure 17. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players in 2024
Figure 18. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2024
Figure 20. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 22. United States Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 26. Germany Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2020-2031)
Figure 34. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 42. Mexico Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 46. Turkey Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 50. Novartis Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 51. Seattle Genetics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 52. Merck Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 54. Genmab AS Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 55. Takeda Pharmaceutical Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 56. Eisai Co., Ltd. Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 57. Cellerant Therapeutics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Others
Table 5. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2020-2025)
Table 9. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2026-2031)
Table 11. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Trends
Table 12. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Drivers
Table 13. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Challenges
Table 14. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Restraints
Table 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players (2020-2025)
Table 17. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2024)
Table 18. Ranking of Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Headquarters and Area Served
Table 21. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Product and Application
Table 22. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Type (2020-2025)
Table 26. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Type (2026-2031)
Table 28. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Application (2020-2025)
Table 30. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Application (2026-2031)
Table 32. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 47. Roche Company Details
Table 48. Roche Business Overview
Table 49. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 50. Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Novartis Company Details
Table 53. Novartis Business Overview
Table 54. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 55. Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Seattle Genetics Company Details
Table 58. Seattle Genetics Business Overview
Table 59. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 60. Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 61. Seattle Genetics Recent Development
Table 62. Merck Company Details
Table 63. Merck Business Overview
Table 64. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 65. Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 66. Merck Recent Development
Table 67. Bristol-Myers Squibb Company Details
Table 68. Bristol-Myers Squibb Business Overview
Table 69. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 70. Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 71. Bristol-Myers Squibb Recent Development
Table 72. Genmab AS Company Details
Table 73. Genmab AS Business Overview
Table 74. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 75. Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 76. Genmab AS Recent Development
Table 77. Takeda Pharmaceutical Company Details
Table 78. Takeda Pharmaceutical Business Overview
Table 79. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 80. Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 81. Takeda Pharmaceutical Recent Development
Table 82. Eisai Co., Ltd. Company Details
Table 83. Eisai Co., Ltd. Business Overview
Table 84. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 85. Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 86. Eisai Co., Ltd. Recent Development
Table 87. Cellerant Therapeutics Company Details
Table 88. Cellerant Therapeutics Business Overview
Table 89. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product
Table 90. Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)
Table 91. Cellerant Therapeutics Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
Table 95. Authors List of This Report
List of Figures
Figure 1. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Picture
Figure 2. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Type: 2024 VS 2031
Figure 4. Chemotherapy Features
Figure 5. Radiation Therapy Features
Figure 6. Others Features
Figure 7. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Report Years Considered
Figure 14. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region: 2024 VS 2031
Figure 17. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players in 2024
Figure 18. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2024
Figure 20. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 22. United States Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 26. Germany Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2020-2031)
Figure 34. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 42. Mexico Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)
Figure 46. Turkey Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 50. Novartis Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 51. Seattle Genetics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 52. Merck Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 54. Genmab AS Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 55. Takeda Pharmaceutical Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 56. Eisai Co., Ltd. Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 57. Cellerant Therapeutics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232